Table 2 Baseline RHC, UCG and CMR characteristics of CTD-PAH patients

n = 74

n = 73

RHC

 mPAP,mmHg

37.0 (33.0–44.8)

48.0 (38.0–52.0)

 PAWP,mmHg

7 (5–10)

8 (6–11)

 PVR,WU

5.43 (3.94–8.79)

9.66 (6.67–14.20)

 mRAP,mmHg

4.00 (3.00–7.00)

6.00 (3.75–8.25)

 mRVP,mmHg

22.0 (17.2–27.0)

27.0 (23.5–34.0)

 CI,L/min/m²

3.10 (2.70–3.69)

2.54 (2.00–3.14)

UCG

 RAD,mm

39 (35–42)

43 (40–48)

 RVDd,mm

40 (37–43)

45 (41–49)

 LAD,mm

32 (29–35)

31 (28–35)

 LVDd,mm

42.6 ± 4.5

38.8 ± 5.7

 IVS,mm

9 (8–10)

10 (9–10)

 LVPW,mm

8 (8–9)

9 (9–10)

 EF,%

65.4 (63.6–66.9)

64.8 (62.7–66.7)

 E'_sep,cm/s

6.47 ± 1.61

5.67 ± 1.47

 E'_lat,cm/s

11.80 ± 3.19

9.14 ± 2.88

 E/A

0.95 (0.80–1.20)

0.90 (0.70–1.00)

 E/e’

7.00 (6.10–8.20)

7.90 (6.40–9.30)

 Tapse,mm

17.30 ± 3.19

15.30 ± 3.30

 Tapse/PASP

0.29 (0.21–0.36)

0.19 (0.16–0.23)

 RV FAC,%

32.9 ± 7.3

28.2 ± 7.3

 TVR,cm/s

374.0 ± 53.8

423.0 ± 55.4

 Pericardial effusion,n(%)

25 (33.8%)

38 (52.8%)

CMR

 LVEF,%

56.2 (51.5–61.3)

57.3 (49.0–62.8)

 LVEDVI,ml/m²

68.9 ± 15.6

54.7 ± 21.1

 LVESVI,ml/m²

29.3 (23.8–38.4)

22.5 (17.6–27.5)

 LVMI,g/m²

43.4 (36.9–48.3)

38.2 (34.2–42.9)

 RVEF,%

39.3 ± 11.6

27.0 ± 10.1

 RVEDVI,ml/m²

89.3 (80.5–115.0)

115.0 (87.1–140.0)

 RVESVI,ml/m²

54.3 (42.6–73.1)

75.1 (62.4–104.0)

 RVMI,g/m²

10.4 (8.0–13.0)

16.1 (11.1–20.1)

 Native T1,ms

1258 (1225–1288)

1285 (1246–1341)

 ECV,%

29.50 ± 7.15

31.10 ± 6.58